🔎 Trials Near Me

Utama › Penyakit Granulomatous Kronik › Maryland

Kajian klinikal Penyakit Granulomatous Kronik di Maryland

6 kajian untuk Penyakit Granulomatous Kronik sedang mencari peserta di lokasi di Maryland.

Teks kajian rasmi (Bahasa Inggeris)

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1
Umur 18 hingga 75 · Lelaki · Dikemas kini 2 Okt 2026 · NCT05189925

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1/2
Umur 4 hingga 65 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05463133

Evaluation of Patients With Immune Function Abnormalities

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Semua umur · Semua jantina · Dikemas kini 22 Sep 2026 · NCT00128973

Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 70 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT00001405

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

  • Home-based telemedicine, Annapolis
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06605378

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1/2
Umur 18 hingga 75 · Lelaki · Dikemas kini 13 Ogo 2026 · NCT06325709

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.